J&J's Janssen Submits Supplemental New Drug Application To FDA For SPRAVATO CIII Nasal Spray For The Rapid Reduction Of Depressive Symptoms In Adults With Major Depressive Disorder Who Have Active Suicidal Ideation With Intent
Benzinga Newsdesk